Opendata, web and dolomites

Pituitary enhancers SIGNED

Identification and functional validation of novel enhancer sequences involved in pituitary gland development and pathology

Total Cost €


EC-Contrib. €






 Pituitary enhancers project word cloud

Explore the words cloud of the Pituitary enhancers project. It provides you a very rough idea of what is the project "Pituitary enhancers" about.

conducting    putative    interactions    verified    variations    chip    functional    cells    physiological    functionally    histone    human    fundamental    preliminary    lag    performed    sanger    silico    expression    health    marks    linked    duplications    gap    validate    pathologies    disorders    tumoral    overexpression    gene    pursuing    tested    regulatory    there    vitro    indicator    perform    gpr101    clinical    mutations    de    accessibility    promoter    normal    structural    screen    chromatin    remarkably    place    transcription    regulation    disrupt    underlying    assays    4c    central    abnormal    luciferase    enhancers    domain    causing    local    showing    elucidate    profile    region    acrogigantism    regulates    methylation    mechanisms    pathological    hypothesis    patients    structure    seq    sequences    characterization    reporter    novo    cnv    children    transcriptional    located    gpr10    creation    tumors    pituitary    enhancer    sequencing    molecular    genome    duplicated   

Project "Pituitary enhancers" data sheet

The following table provides information about the project.


Organization address
address: VIA MANZONI 56
city: ROZZANO (MI)
postcode: 20100

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Italy [IT]
 Total cost 183˙473 €
 EC max contribution 183˙473 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2018
 Funding Scheme MSCA-IF-EF-RI
 Starting year 2020
 Duration (year-month-day) from 2020-03-16   to  2022-03-15


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    HUMANITAS MIRASOLE SPA IT (ROZZANO (MI)) coordinator 183˙473.00


 Project objective

There is a fundamental gap in understanding how the GPR101 gene regulates human growth in physiological and pathological conditions. Children’s growth is remarkably clinical relevant and is an important indicator of their health and general well-being. The specific objective of this proposal is to identify the molecular mechanisms underlying GPR101 overexpression in the pituitary tumors of children with GPR101 duplications causing X-linked acrogigantism (X-LAG). My central hypothesis is that GPR101 duplications disrupt the structure of the local chromatin, leading to the creation of a new chromatin domain where de novo enhancer-promoter interactions take place, causing abnormal GPR101 expression. This hypothesis will be tested by pursuing three specific aims: 1. Elucidate the transcriptional regulation of GPR101 in normal and pathological conditions 2. Identify and functionally characterize novel pituitary-specific enhancer sequences 3. Investigate these regulatory sequences in patients with different pituitary pathologies. To achieve aim 1) I will perform an in vitro functional characterization of GPR101 promoter: promoter activity will be studied by luciferase-based reporter assays, by conducting a methylation analysis, and by determining its accessibility to transcription factors. To achieve aim 2) I will validate my preliminary results showing the formation of a novel chromatin domain by 4C-Seq. Four putative enhancer sequences located within the duplicated GPR10 region and identified in silico will be functionally evaluated in vitro to establish their impact on transcriptional activity. To identify novel pituitary-specific enhancers, a whole-genome profile of enhancer-specific histone marks will be performed in normal and tumoral pituitary cells by ChIP-Seq. To achieve aim 3) I will screen patients with different pituitary disorders for mutations (Sanger sequencing) and structural variations (CNV assays) in the functionally-verified enhancers.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PITUITARY ENHANCERS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PITUITARY ENHANCERS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

SIMIS (2020)

Strongly Interacting Mass Imbalanced Superfluid with ultracold fermions

Read More  

POMOC (2019)

Charles IV and the power of marvellous objects

Read More  

NaWaTL (2020)

Narrative, Writing, and the Teotihuacan Language: Exploring Language History Through Phylogenetics, Epigraphy and Iconography

Read More